Cargando…
The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new virus discovered in December 2019 that causes coronavirus disease 19 (COVID-19) and various vaccinations have been developed. The extent to which COVID-19 infections and/or COVID-19 vaccinations alter antiphospholipid antibodies (...
Autores principales: | Ott, Olivia, Herrmann, Eva, Schulz, Annabel, Lindhoff-Last, Edelgard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051980/ https://www.ncbi.nlm.nih.gov/pubmed/36982716 http://dx.doi.org/10.3390/ijms24065644 |
Ejemplares similares
-
Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry
por: Schulz, Annabel, et al.
Publicado: (2022) -
Evaluation of the sensitivity and specificity of a novel line immunoassay for the detection of criteria and non-criteria antiphospholipid antibodies in comparison to established ELISAs
por: Thaler, Markus A., et al.
Publicado: (2019) -
Neurological and Neuropsychiatric Manifestations of Antiphospholipid-Antibody Syndrome (APS)
por: Asif, Saba, et al.
Publicado: (2022) -
Antiphospholipid antibodies and thrombosis: pathogenesis of antiphospholipid syndrome
por: Koike, T
Publicado: (2003) -
Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome
por: Devreese, Katrien M.J., et al.
Publicado: (2021)